Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structure-Activity Relationships and Discovery of (S)-5-(tert-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-h]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer.
Gotchev D, Chen S, Dugan B, Dorsey BD, Wang X, Sheraz M, Kowalski R, Liu F, Tang S, Chiu T, Harasym T, Graves IE, Thi EP, Mason JD, Overholt N, Dugyala R, Lam AM, Cole AG, Sofia MJ. Gotchev D, et al. J Med Chem. 2024 Nov 28;67(22):20467-20494. doi: 10.1021/acs.jmedchem.4c01928. Epub 2024 Nov 8. J Med Chem. 2024. PMID: 39513566
HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element.
Zhou T, Block T, Liu F, Kondratowicz AS, Sun L, Rawat S, Branson J, Guo F, Steuer HM, Liang H, Bailey L, Moore C, Wang X, Cuconatti A, Gao M, Lee ACH, Harasym T, Chiu T, Gotchev D, Dorsey B, Rijnbrand R, Sofia MJ. Zhou T, et al. Among authors: gotchev d. Antiviral Res. 2018 Jan;149:191-201. doi: 10.1016/j.antiviral.2017.11.009. Epub 2017 Nov 10. Antiviral Res. 2018. PMID: 29133129
Host Poly(A) Polymerases PAPD5 and PAPD7 Provide Two Layers of Protection That Ensure the Integrity and Stability of Hepatitis B Virus RNA.
Liu F, Lee ACH, Guo F, Kondratowicz AS, Micolochick Steuer HM, Miller A, Bailey LD, Wang X, Chen S, Kultgen SG, Cuconati A, Cole AG, Gotchev D, Dorsey BD, Rijnbrand R, Lam AM, Sofia MJ, Gao M. Liu F, et al. Among authors: gotchev d. J Virol. 2021 Aug 25;95(18):e0057421. doi: 10.1128/JVI.00574-21. Epub 2021 Aug 25. J Virol. 2021. PMID: 34191584 Free PMC article.
Structure-Activity Relationships and Discovery of (S)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6H-pyrido[1,2-h][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer.
Gotchev D, Dorsey BD, Nguyen D, Kakarla R, Dugan B, Chen S, Gao M, Bailey L, Liu F, Harasym T, Chiu T, Tang S, Lee AC, Cole AG, Sofia MJ. Gotchev D, et al. J Med Chem. 2024 Jan 25;67(2):1421-1446. doi: 10.1021/acs.jmedchem.3c01981. Epub 2024 Jan 8. J Med Chem. 2024. PMID: 38190324
Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161.
Lam AM, Dugyala RR, Sheraz M, Liu F, Thi EP, Graves IE, Cuconati A, Steuer HM, Ardzinski A, Overholt N, Mason JD, Gotchev D, Cole AG, Harasym TO, Sofia MJ. Lam AM, et al. Among authors: gotchev d. Viruses. 2024 Feb 21;16(3):323. doi: 10.3390/v16030323. Viruses. 2024. PMID: 38543689 Free PMC article.
Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 Mpro from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant Variants.
Wang X, Gotchev D, Fan KY, Vega MM, Mani N, McGovern-Gooch K, Cuconati A, Tercero B, Wang X, Carpino P, Maskos K, Centrella PA, Schmitt A, Preuss F, Prasad A, Chen CY, Clark MA, Guilinger JP, Johnstone S, von König K, Keefe AD, Liu J, Turcotte S, Zhang Y, Konz Makino DL, Lam AM, Cole AG, Sofia MJ. Wang X, et al. Among authors: gotchev d. J Med Chem. 2024 Nov 14;67(21):19623-19667. doi: 10.1021/acs.jmedchem.4c02009. Epub 2024 Oct 25. J Med Chem. 2024. PMID: 39453309
Biological characterization of AB-343, a novel and potent SARS-CoV-2 Mpro inhibitor with pan-coronavirus activity.
McGovern-Gooch KR, Mani N, Gotchev D, Ardzinski A, Kowalski R, Sheraz M, Micolochick Steuer HM, Tercero B, Wang X, Wasserman A, Chen CY, von König K, Maskos K, Prasad A, Blaesse M, Bergmann A, Konz Makino DL, Fan KY, Kultgen SG, Lindstrom A, Nguyen D, Vega M, Wang X, Bracci N, Weiss SR, Cole AG, Lam AM, Cuconati A, Sofia MJ. McGovern-Gooch KR, et al. Among authors: gotchev d. Antiviral Res. 2024 Dec;232:106038. doi: 10.1016/j.antiviral.2024.106038. Epub 2024 Nov 20. Antiviral Res. 2024. PMID: 39577571
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators. Zannad F, et al. N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27. N Engl J Med. 2018. PMID: 30146935 Free article. Clinical Trial.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Free article. Clinical Trial.
37 results